

**Amendments to the Claims:**

Please cancel claims 9-20, amend the claims, and add new claims as follows.

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

**Claim 1.** (Currently Amended) A formulation device for transdermal electrotransport delivery, comprising an electrotransport reservoir containing an aqueous solution of a drug and a dipeptide-peptidic buffer, the dipeptide-peptidic buffer comprising a polypeptide having a chain of 2 to 5 amino acids and having an isoelectric pH at which the dipeptide-polypeptide carries no net charge, the dipeptide-polypeptide having at least 2 pKa's which are separated by no more than about 3.5 pH units, the solution having a pH which is within 1.0 pH units of the isoelectric pH.

**Claim 2.** (Currently Amended) The formulation device of claim 1, wherein the isoelectric pH of the dipeptide-polypeptide is between about 3 and 10.

**Claim 3.** (Currently Amended) The formulation device of claim 1, wherein the dipeptide polypeptide is present in the solution at a concentration of at least about 10 mM.

**Claim 4.** (Currently Amended) The formulation device of claim 1, wherein the dipeptide polypeptide includes at least one amino acid selected from the group consisting of His, Tyr, Arg, Cys, Lys, Asp and Glu.

**Claim 5.** (Currently Amended) The formulation device of claim 1, wherein the dipeptide polypeptide includes His.

**Claim 6.** (Currently Amended) The formulation device of claim 1, wherein the dipeptide polypeptide is Gly-His.

**Claim 7.** (Currently Amended) The formulation device of claim 1, wherein ~~the dipeptide~~ the polypeptide is selected from the group consisting of Asp-Asp, Gly-Asp, Asp-His, Glu-His, His-Glu, His-Asp, Glu-Arg, Glu-Lys, Arg-Glu, Lys-Glu, Arg-Asp, Lys-Asp, His-Gly, His-Ala, His-Asn, His-Citruline, His-Gln, His-Hydroxyproline, His-Isoleucine, His-Leu, His-Met, His-Phe, His-Pro, His-Ser, His-Thr, His-Trp, His-Tyr, His-Val, Asn-His, Thr-His, Try-His, Gin-His, Phe-His, Ser-His, Citruline-His, Trp-His, Met-His, Val-His, His-His, Isoleucine-His, Hydroxyproline-His, Leu-His, Ala-His, Gly-His, Beta-Alanylhistidine, Pro-His, Carnosine, Anserine, Tyr-Arg, Hydroxylysine-His, His-Hydroxylysine, Ornithine-His, His-Lys, His-Ornithine and Lys-His.

**Claim 8.** (Currently Amended) The formulation device of claim 1, wherein the drug comprises a polypeptide or a protein.

**Claim 9. - 20.** (Canceled)

**Claim 21.** (New) The device of claim 1, wherein the peptidic buffer is at a pH one of being slightly higher than the polypeptide's pI in a cathodic reservoir from which a drug therein is to be delivered and being slightly lower than the polypeptide's pI in an anodic reservoir from which a drug therein is to be delivered.

**Claim 22.** (New) The device of claim 1, wherein the peptidic buffer is at a pH one of being 0.5 to 1 unit higher than the polypeptide's pI in a cathodic reservoir from which a drug therein is to be delivered and being 0.5 to 1 unit lower than the polypeptide's pI in an anodic reservoir from which a drug therein is to be delivered.

**Claim 23.** (New) The device of claim 1, wherein the device is iontophoretic and comprising a donor electrode contacting the reservoir containing the drug.

**Claim 24.** (New) The device of claim 1, wherein the device is iontophoretic and further comprising a second reservoir counter to the reservoir containing the drug, the second reservoir containing electrolyte and a peptidic buffer, the peptidic buffer comprising a polypeptide having a chain of 2 to 5 amino acids and having an isoelectric pH at which the polypeptide carries no net charge, the polypeptide having at least 2 pKa's which are separated by no more than about 3.5 pH units, the solution having a pH which is within 1.0 pH units of the isoelectric pH.

**Claim 25.** (New) A method of making a device for transdermal electrotransport delivery, comprising including in the device an electrotransport reservoir containing an aqueous solution of a drug and a peptidic buffer, the peptidic buffer comprising a polypeptide having a chain of 2 to 5 amino acids and having an isoelectric pH at which the polypeptide carries no net charge, the polypeptide having at least 2 pKa's which are separated by no more than about 3.5 pH units, the solution having a pH which is within 1.0 pH units of the isoelectric pH.

**Claim 26.** (New) The method of claim 25, comprising including a polypeptide with an isoelectric pH of between about 3 and 10.

**Claim 27.** (New) The method of claim 25, comprising including the polypeptide in the solution at a concentration of at least about 10 mM.

**Claim 28.** (New) The method of claim 25, wherein the polypeptide includes at least one amino acid selected from the group consisting of His, Tyr, Arg, Cys, Lys, Asp and Glu.

**Claim 29.** (New) The method of claim 25, wherein the polypeptide includes His.

**Claim 30.** (New) The method of claim 25, wherein the polypeptide is Gly-His.

**Claim 31.** (New) The method of claim 25, wherein the polypeptide is selected from the group consisting of Asp-Asp, Gly-Asp, Asp-His, Glu-His, His-Glu, His-Asp, Glu-Arg, Glu-Lys, Arg-Glu, Lys-Glu, Arg-Asp, Lys-Asp, His-Gly, His-Ala, His-Asn, His-Citruline, His-Gln, His-Hydroxyproline, His-Isoleucine, His-Leu, His-Met, His-Phe, His-Pro, His-Ser, His-Thr, His-Trp,

His-Tyr, His-Val, Asn-His, Thr-His, Try-His, Gin-His, Phe-His, Ser-His, Citruline-His, Trp-His, Met-His, Val-His, His-His, Isoleucine-His, Hydroxyproline-His, Leu-His, Ala-His, Gly-His, Beta-Alanylhistidine, Pro-His, Carnosine, Anserine, Tyr-Arg, Hydroxylysine-His, His-Hydroxylysine, Ornithine-His, His-Lys, His-Ornithine and Lys-His.

**Claim 32.** (New) The method of claim 25, comprising including a polypeptide or a protein as the drug.

**Claim 33.** (New) The method of claim 25, comprising including the peptidic buffer at a pH one of being slightly higher than the polypeptide's pI in a cathodic reservoir from which a drug therein is to be delivered and being slightly lower than the polypeptide's pI in an anodic reservoir from which a drug therein is to be delivered.

**Claim 34.** (New) The method of claim 25, comprising including the peptidic buffer at a pH one of being 0.5 to 1 unit higher than the polypeptide's pI in a cathodic reservoir from which a drug therein is to be delivered and being 0.5 to 1 unit lower than the polypeptide's pI in an anodic reservoir from which a drug therein is to be delivered.